Last reviewed · How we verify
NCT07172971: CHERISH
Sodium/Glucose Cotransporter-2 Inhibitors (SGLT2i) Therapy in Duchenne Cardiomyopathy
Phase 1 trial testing SGLT-2 inhibitor in Duchenne Muscular Dystrophy (DMD) in 10 participants. Not yet recruiting.
1 August 2027
Quick facts
| Lead sponsor | Larry W. Markham |
|---|---|
| Phase | Phase 1 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | other |
| Enrollment | 10 |
| Start date | 1 February 2026 |
| Primary completion | 1 August 2027 |
| Estimated completion | 1 February 2028 |
| Sites | 1 location across United States |
Drugs / interventions tested
- SGLT-2 inhibitor — full drug profile →
- SGLT2 inhibitor — full drug profile →
Conditions studied
- Duchenne Muscular Dystrophy (DMD) — all drugs for Duchenne Muscular Dystrophy (DMD) →
Sponsor
Larry W. Markham
Who can join
Adults 8 to 18, male only, with Duchenne Muscular Dystrophy (DMD). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a pharmacokinetic study (PK Study) to better understand empagliflozin dosing in pediatric Duchenne muscular dystrophy patients. Empagliflozin is currently used off-label in this population due to the mortality benefits seen in adult cardiomyopathy and heart failure. Investigators will perform PK studies in DMD patients of various ages and weights to better understand the PK profile (absorption, distribution, metabolism, excretion) and dosing to better treat Duchenne cardiomyopathy.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07172971
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of SGLT-2 inhibitor
Trials testing the same drug.
- NCT07272057 — SGLT2 Inhibitors and Survival in Lung Cancer Patients With Diabetes · NA · not yet recruiting
- NCT07143773 — SGLT2i Safety and Efficacy on Kidney Allograft Function in Non-diabetic Kidney Transplant Recipients · Phase 4 · recruiting
- NCT06905405 — The Use of Advanced Imaging in HFpEF · recruiting
- NCT07325435 — Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists · Phase 4 · active not recruiting
- NCT06753994 — Continuous Ketone Monitoring in People With Type 1 Diabetes Using SGLT2 Inhibitors · Phase 1 · recruiting
Other recruiting trials for Duchenne Muscular Dystrophy (DMD)
Currently open trials in the same condition.
- NCT07038824 — A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping to Evaluate the Safety and Efficac · Phase 1, PHASE2 · recruiting
- NCT07129954 — Fear of Falling in Muscular Dystrophy · NA · recruiting
- NCT07037862 — A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping to Evaluate the Safety and Efficac · Phase 1, PHASE2 · recruiting
- NCT06755138 — Research on the Relationship Between Scoliosis, Pain, Quality of Life, and Trunk Muscle Compensation Patterns Among Pati · recruiting
- NCT06773988 — Follow-up of NIV At Home in Patients with Duchenne Muscular Dystrophy · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07172971 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Larry W. Markham
- Last refreshed: 24 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07172971.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing